CD274 and non-small cell lung carcinoma: Looking at immunotherapy as an adjuvant strategy after curative-intent surgery for early NSCLC, atezolizumab was the first ICI to receive FDA approval as adjuvant therapy for PD-L1 expressing stage II to IIIA NSCLC following surgical resection and completion of adjuvant cisplatin-based chemotherapy, based on the results of phase III trial IMpower 010.